Development and Value of a Centralized Text Message-based Tracking and Support Program for the PRECIDENTD

Sep 30, 2026

PRECIDENTD is a PCORnet Study evaluating two medication classes—SGLT2 inhibitors and GLP-1 receptor agonists—in adults with type 2 diabetes. Participants receive assigned treatment via health insurance and complete semi-annual assessments. Partners co-designed a centralized text message program using MEMOTEXT to support adherence and retention from April 2024 to April 2025. Outcomes included interactive response rates, messages flagged for additional support, and adherence-related issues, identifying problems prompting outreach calls.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Background

Objective

Methods

Measures

Results

Conclusions

Development and Value of a Centralized Text Messagebased Tracking and Support Program for the PRECIDENTD Study Lyndsay A. Nelson, PhD,* Erin M. Bergner, PhD, MPH,* Amos Adler, MSc,† Charles Yoon, PhD,† Kathleen Mieras, BA, CCRP,‡ Ed Simeone, MA,§ Jeremy I. Lema-Driscoll, BA,∥ Brendan M. Everett, MD, MPH, ∥ Deborah J. Wexler, MD, MSc,¶ and Lindsay S. Mayberry, MS, PhD* Background: PRECIDENTD (PRevention of CardIovascular and DiabEtic KidNey Disease in Type 2 Diabetes) is a PCORnet® Study evaluating 2 classes of medications, SGLT2 inhibitors and GLP-1 receptor agonists, among people with type 2 diabetes. Participants obtain their assigned medication through their health insurance and complete semi-annual study assessments. Objective: We engaged multiple partners to develop a centralized text message-based program to facilitate adherence and retention in PRECIDENTD and evaluated its performance from April 2024 to April 2025 . Methods: The PRECIDENTD study team applied best practices in digital health tool design and built the program with technology company MEMOTEXT. Patient partners identiﬁed program goals, co-wrote message content, and completed internal testing. We then deployed the program to PRECIDENTD participants and analyzed responses. Measures: We assessed response rate to interactive text messages, proportion of messages ﬂagging participants needing additional support, and the adherence problems identiﬁed. Results: The text messaging program includes interactive messages querying if participants are taking the study medication, as well as one-way study timeline messages. During the ﬁrst year, 450 PRECIDENTD participants across 20 sites received texts. Interactive message response rate was 80%, and 25% of responses identiﬁed problems (ie, trouble getting ﬁlls/reﬁlls and experiencing a health concern or side effect), prompting an outreach call. Conclusions: We co-designed a digital tool that engaged participants and helped identify study participants needing assistance obtaining and adhering to study medications. Collaborative development of similar centralized tools may augment the capacity of national studies to answer important comparative effectiveness research questions. Key Words: technology, comparative studies, adherence, randomized trial (Med Care 2026;64:S242–S250) P CORnet® is a large, integrated national research net work that facilitates comprehensive analysis of patient health outcomes while engaging patients in the research process.1 It supports the efﬁcient conduct of comparative clinical effectiveness research (CER) that directly compares the beneﬁts and harms of different treatment options, with the goal of providing evidence to help meet the real-world needs of patients, providers, and health care systems.2–5 Pragmatic, multisite CER trials ask which treatments work best (and for whom, in what contexts) among patients with diverse medical and demographic characteristics who are seen in routine clinical practice, From the *Department of Medicine, Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN; †MEMOTEXT Corporation, Toronto, Ontario, Canada; ‡Patient Partner, PRECIDENTD Executive Committee, Rochester, MN; §Patient Partner, PRECIDENTD Executive Committee, Nashua, NH; ∥Divisions of Cardiovascular and Preventive Medicine, Brigham and Women’s Hospital, Boston, MA; and ¶Diabetes Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA. The PRECIDENTD Study is funded by the Patient Centered Outcomes Research Institute, Phased Large Awards for Comparativeness Effectiveness Research (PCORI PLACER-2020C3-21005) . The use of REDCap and the Community Engagement Studio were supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. The manuscript contents are solely the responsibility of the authors and do not necessarily represent ofﬁcial views of the National C

FAQs

What is PRECIDENTD and what treatments does it evaluate?

PRECIDENTD evaluates two medication classes—SGLT2 inhibitors and GLP-1 receptor agonists—among people with type 2 diabetes.

How was the centralized text message program developed and implemented?

The team used best practices in digital health tool design and built the program with MEMOTEXT, with patient partners defining goals, co-writing message content, and completing internal testing. The program was then deployed to participants and responses were analyzed.

What did the program measure, and what were key results?

It measured interactive response rate to text messages, the proportion of messages flagging participants needing additional support, and adherence problems identified. In the first year, 450 participants across 20 sites received texts; the interactive response rate was 80%, and 25% of responses identified problems prompting outreach calls.

Sep 30, 2026

Uploaded by Alex Sinclair